Evidence map›Paper›PMID 30627093›Full record

ArticleCase reports in oncology

Gastrointestinal Perforation after Rituximab Therapy in Mantle Cell Lymphoma: A Case Report.

Michael Adashek, Abigail Chan, Adriana Medina

Open access · goldAbstract readCase Reports
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Michael AdashekDepartment of Internal Medicine, Sinai Hospital, Baltimore, Maryland, USA.
Abigail ChanDepartment of Internal Medicine, Sinai Hospital, Baltimore, Maryland, USA.
Adriana MedinaDepartment of Hematology/Oncology, Sinai Hospital, Baltimore, Maryland, USA.
Sinai Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mantle cell lymphoma (MCL) is a rare form of non-Hodgkin lymphoma (NHL), responsible for 2.8% of all NHL cases within the United States. The majority of patients with MCL present with advanced disease, 10-20% of which have extra-nodal involvement at diagnosis. The gastrointestinal presence of lymphoma can lead to gastrointestinal perforation, resulting in significant morbidity from peritonitis and sepsis while prolonging hospitalizations and delaying treatment. In this case we discuss a 55-year-old male with newly diagnosed MCL who developed peritonitis 9 days after initiation of dose reduced rituximab due to gastrointestinal perforation. Although prognostication factors for MCL such as the mantle cell lymphoma international prognostic index (MIPI) score exist, further research is needed to stratify risk factors for morbid treatment complications such as gastrointestinal perforation.

Indexed as

Gastrointestinal PerforationMantle Cell Lymphoma

Identifiers

PMID30627093
PMCPMC6323410
OpenAlexW2902952720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.